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THE SUCCESS OF AUTOLOGOUS TRANSPLANT FOR PEDIATRIC RE-
LAPSED/REFRACTORY HODGKIN LYMPHOMA IS MOST INFLUENCED BY
THE DISEASE STATUS PRE-TRANSPLANT
Margossian, S.P.,Williams, T., Billett, A.L., Duncan, C., Lehmann, L.E.
Dana Farber/Children’s Hospital Cancer Center, Boston, MA
Background: Autologous peripheral blood stem cell transplant
(aPBSCT) is a standard treatment approach for patients with re-
lapsed or refractory Hodgkin Lymphoma (HL). The current liter-
ature suggests the 3 year event free survival for HL patients
following aPBSCT ranges from 40-65% with 5% events due
to transplant related mortality and recurrent disease accounting
for the rest.
Methods:We conducted a retrospective analysis of all pediatric pa-
tients who were transplanted for HL at the DF/CHCC from 1/1/00
to 12/31/09. 24 patients with refractory (n5 9) or relapsed (n5 15)
HL underwent aPBSCT, including 2 patients with multiple relapses
and one with initial refractory disease who subsequently progressed
prior to aPBSCT (scored as refractory). Any patient whose disease
progressed during first therapy was considered refractory, even if
there was an initial disease response.
Patients:There were 13 males and 11 females analyzed, average age
14 yrs (8 yr-20.5 yr). Disease stage at presentation ranged from IIa to
IVb. Histology included NS (n 5 20), mixed cellularity (n 5 3) and
LP (n5 1). Disease progression/recurrence was confirmed by biopsy
in 22 of 24 patients. Salvage regimens varied, with ICE (n5 12) and
venorelbine regimens (n 5 9) most common.
Results: 22/24 patients came to transplant in CR (defined as
negative functional study and . 50% tumor response by CT);
1/24 in VGPR (defined as negative functional study and\ 50%
CT response) and 1/24 with active disease on PET with 50% re-
sponse by CT. All patients were conditioned with BEAM
(carmustine/etoposide/cytarabine/melphalan) followed by reinfu-
sion of cryopreserved autologous cells. There was 1 toxic death
at day +12 (4%) in a patient previously intubated for Stevens-
Johnson syndrome, and 1 relapse (4%) occurring 6 months after
aPBSCT.
Conclusion: aPBSCT is a proven modality to salvage patients with
HL who fail frontline therapy. In our series, conditioning with
BEAM followed by aPBSCT had a TRM (4 %) consistent with
that reported for autologous transplant. Disease progression was
seen in only one patient. Notably this was the only patient with func-
tional evidence of active disease at time of transplant. 92% (22/24) of
patients who presented for aPBSCT are alive and well with a median
follow-up of 60 months. Length of first CR, stage of disease or num-
ber of relapses prior to transplant did not seem to impact survival.
These results suggest achieving excellent EFS is most influenced
by disease control pre-aPBSCT.314
PROCALCITONIN IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANT (AHSCT) RECIPIENTS
Watson, T.M.1, Fry, T.J.2, Jacobsohn, D.A.1, Sande, J.1,3, Yates, B.1,
Stevenson, A.1 1Children’s National Medical Center, Washington, DC;
2Center for Cancer Research, NCI, NIH, Bethesda, MD; 3George Wash-
ington University School of Medicine, Washington, DC
The mortality of aHSCT remains unacceptably high and is of-
ten related to inflammation from infection and/or graft-versus-
host disease (GVHD). Identifying markers of inflammation may
allow tailoring of therapy in high-risk patients (pts). Studies
show PCT as a useful marker in assessing the severity of bacterial
infections. We conducted a prospective pilot study measuring
serial procalcitonin (PCT) and other inflammatory markers in pe-
diatric aHSCT pts. The goal of this ongoing study is to identify
biomarkers that would be predictive of infection and other post-
transplant complications.
Pts were enrolled prior to preparative regimen, and serum was
collected pre-transplant, day of stem cell infusion (D0), biweeklyuntil engraftment, and on day 30, 60, and 100. Samples were
run using Time Resolved Amplified Cryptate Emission technol-
ogy.
Thirteen pts have been enrolled, with a median age of 10 (1-21)
years and the following diagnoses: AML (4), ALL (2), bone marrow
failure (4), thalassemia (2), and sickle cell disease (1). Stem cell
sources include HLA matched related donor (4), matched unrelated
donor (8), and sibling cord (1). The conditioning regimen was abla-
tive in 7 and reduced intensity in 6.
To date, we have pre-transplant and D0 data on all pts. Median
PCT values showed significant differences at the 2 time points
(pre-transplant 0.105 ng/dl [0.000-0.350] vs D0 0.315 ng/dl
[0.035-7.230], p 0.02] with no effect from conditioning regimen.
Of pts with blood culture positive sepsis (2), neither had PCT .
2.0 ng/dl. Pts with GVHD (6) did not have an elevation in PCT.
One pt requiring intensive care for acute renal failure and develop-
ment of respiratory failure due to parainfluenza had significantly el-
evated PCT (peak 20 ng/dl).
This data suggest that an elevation in PCT on D0 is associated
with inflammation caused by preparative regimens. Although the
exact mechanism of PCT is unknown, it is hypothesized that
PCT synthesis is induced by TNF-a or IL-6, which are known
to play a role in preparative regimen-induced inflammation. We
are currently measuring GM-CSF, IFN-g, IL-1b, IL-2, IL-6,
IL-8, IL-10, IL-12p70, and TNF-a by multiplex assay to corre-
late with PCT levels and clinical outcomes. We hypothesize
that PCT will be lower on DO after reduced intensity regimens
given less inflammation and toxicity. More subjects need to be
enrolled to determine whether D0 levels are predictive of toxicity
and whether post-transplant PCT can predict GVHD and/or
infection.315
PHERIPHERAL BLOOD STEM CELL COLLECTION IN AUTOLOGOUS STEM
CELL TRANSPLANTATION, EXPERIENCE IN A SINGLE PEDIATRIC CENTER
IN COLOMBIA
Chaparro, M., Estupi~nan, M. Hospital de la Misericordia, Bogota, DC,
Colombia
Between August 2007 and December 2009 all patients with ma-
lignancies those that were candidates to autologous stem cell
transplantation had been included. All patients were mobilized
by chemotherapy and G-CSF 5 mgr/kg/day, leukapheresis was
performed when the leukocytes were . 1,000/l. All patients had
a long time catheter Hickman-Broviac or high flow hemodyalisis
catheter through a jugular or subclavian vein, inserted by pediatric
surgery team. All procedures were performed by the continuous
flow blood cell separator Amicus- Fenwal by using manufacturer
provided mononuclear cell computer software. The extracorpo-
real volume of the device is 163 ml and the extracorporeal eryth-
rocyte volume is 79 ml during the mononuclear collection phase.
Between all available devices in Colombia Amicus has the lower
extracorporeal volume. Amicus device has been tested in adults
and children. To avoid cardiovascular effects some children with
low hemoglobin level received irradiated packed RBC without
priming the system as described previously in children with
a weigh lower than 15kg.
A total of 16 procedures were performed in 12 patients, 8 females,
and 4 males. Diagnoses were: neuroblastoma n5 8 lymphoma n5 3
(Hodgkin Lymphoma 2, Large B Cell lymphoma 1), Ewing’s Sar-
coma n5 1. Themedian age was 7 years (2- 17 years) and themedian
weigh 23,5 Kg (12- 50 Kg). The median collection time was 281,2
min. (163- 391 min.), the blood volume processed was 8568,6 ml
(range 1349- 5566 ml), blood volume was processed in a median of
2,5 times (range 2,5- 7 times), all procedures were large-volume leu-
kapheresis. Median weight of product was 107 gr. (Range 45- 155
gr.)The median number of PBPC collected was 4,8 mononuclear
cells (MNC)108/kg (range 0,2–21) and 8,41 CD34+ cells106/kg
(range 0.08– 54).
No circulatory side effects were observed during the procedures.
No one patient required sedation and the only symptoms observed
were associated to hypocalcaemia (muscle spasms of hands in tree pa-
tient weighs 14, 15 y 17Kg). In those patients median blood volume
processed was 6,3 times.
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MOYAMOYA SYNDROME TREATED WITH ENCEPHALODUROARTERIOSY-
NANGIOSIS FOLLOWED BY BONE MARROW TRANSPLANTATION IN
A PATIENT WITH SICKLE CELL DISEASE: A CASE REPORT
Klein, O.1, Goodrich, J.T.2, Schubert, R.3, Sadanandan, S.4, Roman, E.1,
Del Toro, G.1 1Mount Sinai Medical Center, New York, NY; 2Children’s
Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY;
3New YorkMethodist Hospital, Brooklyn, NY; 4BrooklynHospital Center,
Brooklyn, NY
Background: Patients with sickle cell disease (SCD) have a high
risk of intracranial large vessel vasculopathy. This can lead to
a proliferation of microvasculature at the base of the brain known
as moyamoya syndrome. If untreated, there is a high risk of intra-
ventricular hemorrhage and permanent neurologic deficits. There
have been several reports describing patients with SCD and
moyamoya syndrome successfully undergoing revascularization
procedures, including encephaloduroarteriosynangiosis (EDAS).
Hematopoietic cell transplantation from a compatible sibling is
the most effective way of preventing central nervous system
(CNS) complications in SCD patients at risk for CNS events.
To our knowledge, there have been no reports of SCD patients
undergoing EDAS followed by bone marrow transplantation
(BMT).
Case:We describe the case of a 14-year-old girl with SCD who de-
veloped severe stenosis of the right internal carotid artery, which
progressed and extended to the anterior cerebral andmiddle cerebral
arteries, with silent infarcts and changes on magnetic resonance an-
giography (MRA) consistent with moyamoya syndrome. Due to
worsening of her stenosis, at the age of 11 she underwent EDAS
without complications. Eighteenmonths after the procedure, she de-
veloped a left lower extremity monoparesis. Magnetic resonance im-
aging (MRI) did not show any new areas of ischemia. Three months
later she underwent high-dose chemo-immunotherapy followed by
BMT from her compatible sibling. Her mixed-donor chimerism
on day +32 was 98% donor, with concomitant hemoglobin S of
0.9%, confirming donor engraftment and eradication of her SCD.
The patient is now 10 months post-transplant and has not had any
SCD-related complications. Her neurologic exam and neuroimag-
ing studies remain stable.
Conclusion: This is the first case report of EDAS successfully fol-
lowed by BMT in a patient with SCD and moyamoya syndrome.
BMT is considered standard of care in patients with SCD at risk
for CNS complications, leading to stroke-free survival rates of 93-
96%. Patients with moyamoya syndrome and SCD who have
a CNS event are more than twice as likely to experience a recurrent
CNS complication even while on chronic transfusions. Transplant-
eligible SCDpatients who developmoyamoya syndromemay benefit
from EDAS prior to undergoing BMT in order to minimize peri-
and post-transplant CNS complications. Further investigation is
needed to determine the long-term outcome of this therapeutic com-
bination.317
BK-VIRUS ASSOCIATED HEMORRHAGIC CYSTITIS IN CHILDREN FOLLOW-
ING HAEMATOPOIETIC STEM CELL TRANSPLANTATION. A SIX YEARS
EXPERIENCE IN ONE PEDIATRIC BONE MARROW TRANSPLANTATION
CENTER
Zaidman, I.1, Harlev, D.1, Abdalla, K.1, Shachor-Meyouhas, Y.2,
Kra-Oz, Z.3, Kassis, I.2 1Rambam Health Care Campus, Haifa, Israel;
2Rambam Health Care Campus, Haifa, Israel; 3Rambam Health Care
Campus, Haifa, Israel
Introduction: Hemorrhagic cystitis (HC) is a common complica-
tion after haematopoietic stem cell transplantation (HSCT).
Urotropic viruses may cause late-onset HC (BK virus {BKV}, adeno-virus, CMV) associated with severe immunosuppression. Treatment
is mainly symptomatic. The incidence and severity of HC depends
on primary disease, pre-transplant viral status, conditioning, immu-
nosuppressive drugs, source of graft and Graft-versus-Host Disease.
Objectives:: to review the incidence, severity, treatment and
outcome of BKV associated HC post HSCT.
Methods: Patients with BKV associated HC were identified retro-
spectively, reviewing electronic charts of all hospitalized children
in 2004-2010. Diagnosis of BKV is made by a standard Blood and
urine PCR method.
Results: BKV associated HC developed in 11children, during the
study period. One patient had primary immune deficiency and
lymphoma. There were 42 patients with autologous BMT, none
of them had HC. In 10/81 (12%) HC developed after allogeneic
HSCT. Nine patients received Antithymoglobulin (ATG) in com-
bination with high dose of Cyclophosphamide, steroids or total
body irradiation and developed symptoms of HC in the first 3
months after BMT. In 5/10 children Blood CMV reactivation oc-
curred concomitantly. The last 3 patients were treated with low
dose cidofovir (1mg/kg) weekly and 1 patient received a combina-
tion of parenteral and intravesicular cidofovir with an excellent ef-
fect consisting of rapid clinical recovery after 2 doses and
significant decreasing of BK viral load in blood and urine without
side effects. The improvement was more prominent with tapering
down of immune suppressive medications and immune reconstitu-
tion after HSCT.
Conclusion:BKHC is a severe complication after allogeneicHSCT
children. ATG combined with TBI or Cyclophosphamide is a signif-
icant risk factor. Low dose cidofovir could be the option for the treat-
ment of BK infection in combination with symptomatic treatment
until immunological recovery after HSCT.318
REDUCED INTENSITY CONDITIONING FOR SECOND HEMATOPOIETIC
CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH RELAPSED
ACUTE MYELOID LEUKEMIA FOLLOWING ALLOGENEIC TRANSPLANTA-
TION
Mehta, P.A.1, Kim, M.2, Filipovich, A.H.1, Bleesing, J.J.1, Jodele, S.1,
Bellman, D.1, Mueller, M.1, Kotila, S.1, Marsh, R.A.1, Jordan, M.B.1,
Grimley, M.S.1, Myers, K.C.1, Joshi, S.1, Kumar, A.1, Davies, S.M.1
1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Reduced-intensity conditioning (RIC) regimens have extended
the availability of allogeneic hematopoietic cell transplantation
(HCT) to a large group of previously ineligible adult patients with
hematological malignancies. To address whether this is a feasible ap-
proach for secondHCT in children with relapsed acute myeloid leu-
kemia (AML) following allogeneic HCT, we evaluated outcomes of
patients with AML transplanted using RIC at our center, between
2005-2010.
Nine out of total 10 patients with relapsed AML following al-
logeneic HCT were in CR2 or higher disease status at the time
of second HCT (table). Type of grafts included bone marrow
(5), peripheral blood stem cells (1), and umbilical cord blood
(4), that were obtained from matched unrelated donors in 9 pa-
tients and matched sibling donor in 1. All patients received RIC
containing Fludarabine 25mg/m2 from day-8 through Day-4
and Melphalan 140mg/m2 on day -3. One patient with baseline
chromosomal sensitivity was transplanted in CR1, with 50% re-
duction in Melphalan dose (70mg/m2). Graft versus host disease
(GVHD) prophylaxis included cyclosporine (CSA) and Mycophe-
nolate mofetil (MMF) in 7 patients, CSA with steroids in 1 and
tacrolimus with MMF in remaining 2 patients.
All 10 patients tolerated the RIC well without any major compli-
cations or organ dysfunction. All achieved sustained neutrophil en-
graftment, and 9/10 achieved platelet engraftment. Serious
infections included Candida fungemia (2 patients), that responded
well to antifungal therapy. At a median follow-up of 41.4 months
(range 2.5-56.3), 5 patients are alive, and remain disease free, includ-
ing all 4 patients who developedGVHD (Table) and the patient with
underlying chromosomal sensitivity. Of note, 3 of these patients have
